News

Article

Pharmaceutical Technology Europe

Pharmaceutical Technology Europe

Pharmaceutical Technology Europe-06-01-2011
Volume23
Issue 6

Optimising High-Potency Manufacture

Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.

High-containment manufacturing, whether for an active pharmaceutical ingredient or finished drug product, requires specialized approaches in facility design, equipment selection, and manufacturing processes to achieve the desired levels of containment and minimize operator exposure. As with pharmaceutical manufacturing overall, science- and risk-based approaches to reach those goals serve as a crucial framework for optimizing high-potency manufacturing as well for specific elements in the process.

This article was also published in our US sister publication Pharmaceutical Technology and can be read here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
 Benjamin McLeod and Sebastian Lykke Skafte Andersen go behind the headlines to examine the motivations behind recent M&A activity, tariff responses, and more.
Drug Digest: Patient Preference Drives Solid Dosage Trends